Targeting the Warburg Effect in Cancer: Where Do We Stand?
International Journal of Molecular Sciences · 08.03.2024 · 25 (6) · 3142
DOI: 10.3390/ijms25063142 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.03.2024. Verfasst von Ignasi Barba und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Vic-Central University of Catalonia, 08500 Vic, Catalonia, Spain. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 266-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Fundación Asociación Española contra el Cáncer (AECC), ISCIII, FIS.
Abstract (Originalsprache)
The Warburg effect, characterized by the preferential conversion of glucose to lactate even in the presence of oxygen and functional mitochondria, is a prominent metabolic hallmark of cancer cells and has emerged as a promising therapeutic target for cancer therapy. Elevated lactate levels and acidic pH within the tumor microenvironment (TME) resulting from glycolytic profoundly impact various cellular populations, including macrophage reprogramming and impairment of T-cell functionality. Altogether, the Warburg effect has been shown to promote tumor progression and immunosuppression through multiple mechanisms. This review provides an overview of the current understanding of the Warburg effect in cancer and its implications. We summarize recent pharmacological strategies aimed at targeting glycolytic enzymes, highlighting the challenges encountered in achieving therapeutic efficacy. Additionally, we examine the utility of the Warburg effect as an early diagnostic tool. Finally, we discuss the multifaceted roles of lactate within the TME, emphasizing its potential as a therapeutic target to disrupt metabolic interactions between tumor and immune cells, thereby enhancing anti-tumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Vic-Central University of Catalonia, 08500 Vic, Catalonia, Spain.
- Vall d'Hebron Institute of Oncology (VHIO), CIBERONC, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
- Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.
Förderung
- Instituto de Salud Carlos III
- Fundación Asociación Española contra el Cáncer (AECC)
- ISCIII, FIS
- BBVA (CAIMI)
- Cellex Foundation
Zitieren
APA
Barba, I., Carrillo-Bosch, L., & Seoane, J. (2024). Targeting the Warburg Effect in Cancer: Where Do We Stand?. International Journal of Molecular Sciences, 25(6), 3142. https://doi.org/10.3390/ijms25063142
Vancouver
Barba I, Carrillo-Bosch L, Seoane J. Targeting the Warburg Effect in Cancer: Where Do We Stand?. International Journal of Molecular Sciences. 2024;25(6):3142. doi:10.3390/ijms25063142
BibTeX
@article{Barba2024,
author = {Barba, Ignasi and Carrillo-Bosch, Laura and Seoane, Joan},
title = {Targeting the Warburg Effect in Cancer: Where Do We Stand?},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {6},
pages = {3142},
doi = {10.3390/ijms25063142}
}
EUVIMED